1. Home
  2. CIA vs MGNX Comparison

CIA vs MGNX Comparison

Compare CIA & MGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Citizens Inc. ($1.00 Par)

CIA

Citizens Inc. ($1.00 Par)

HOLD

Current Price

$3.51

Market Cap

300.3M

Sector

Finance

ML Signal

HOLD

Logo MacroGenics Inc.

MGNX

MacroGenics Inc.

HOLD

Current Price

$4.14

Market Cap

280.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CIA
MGNX
Founded
1969
2000
Country
United States
United States
Employees
N/A
N/A
Industry
Life Insurance
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
300.3M
280.3M
IPO Year
1995
2013

Fundamental Metrics

Financial Performance
Metric
CIA
MGNX
Price
$3.51
$4.14
Analyst Decision
Buy
Analyst Count
0
5
Target Price
N/A
$5.00
AVG Volume (30 Days)
105.9K
390.3K
Earning Date
05-07-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$255,616,000.00
$149,500,000.00
Revenue This Year
$3.10
N/A
Revenue Next Year
$4.47
$3.19
P/E Ratio
$28.23
N/A
Revenue Growth
4.33
N/A
52 Week Low
$3.39
$1.30
52 Week High
$6.54
$5.08

Technical Indicators

Market Signals
Indicator
CIA
MGNX
Relative Strength Index (RSI) 31.45 50.10
Support Level N/A $3.85
Resistance Level $4.04 $4.50
Average True Range (ATR) 0.18 0.21
MACD 0.01 -0.01
Stochastic Oscillator 13.53 38.23

Price Performance

Historical Comparison
CIA
MGNX

About CIA Citizens Inc. ($1.00 Par)

Citizens Inc is an insurance holding company serving the life insurance needs of individuals in the United States. The company provides insurance benefits to residents in thirty two U.S. states and more than seventy countries through its insurance subsidiaries. The company operates in two business segments namely the Domestic Insurance and International Insurance segments.. The company majority generates revenues from Life Insurance segment. Company operates in USA, Columbia, Taiwan, Venezuela, Ecuador, Argentina, and Others.

About MGNX MacroGenics Inc.

Macrogenics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for the treatment of cancer. The company is currently developing therapeutics utilizing multiple modalities, including antibody-drug conjugates (ADCs) and multi-specific antibodies (which it refers to as DART and TRIDENT molecules). It is advancing three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload. Its segment is developing and commercializing monoclonal antibody-based therapeutics.

Share on Social Networks: